Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fibrogen Inc CS (NQ: FGEN )

18.60 -0.81 (-4.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 932,612
Open 19.30
Bid (Size) 17.94 (1)
Ask (Size) 20.33 (1)
Prev. Close 19.41
Today's Range 18.56 - 19.69
52wk Range 7.810 - 25.69
Shares Outstanding 94,182,915
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Why did Sarepta Therapeutics Stock Plummet?
SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating. 
Via MarketBeat
Exposures Product Safety
FibroGen's Return On Capital Employed Insights
 
Via Benzinga

Performance

YTD
+16.61%
+16.61%
1 Month
-17.70%
-17.70%
3 Month
+18.10%
+18.10%
6 Month
+53.59%
+53.59%
1 Year
+39.74%
+39.74%

More News

Read More
Analyst Ratings for FibroGen
Via Benzinga
FibroGen Shares Gain As Analyst Creates Bullish Pitch On Pulmonary Fibrosis Opportunity
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023
Via Benzinga
B of A Securities Upgrades FibroGen: Here's What You Need To Know
Via Benzinga
Short Volatility Alert: FibroGen, Inc.
Via Benzinga
Recap: FibroGen Q2 Earnings
Via Benzinga
Earnings Scheduled For February 27, 2023
Via Benzinga
Earnings Preview For FibroGen
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 26, 2023
Via Benzinga
Perrigo, Tripadvisor, Lyft, And Some Other Big Stocks Moving Lower On Tuesday
Via Benzinga
Why ABVC BioPharma Shares Are Trading Higher By 129%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
FibroGen Earnings Preview
Via Benzinga
7 Unknown Biotech Stocks That Could Rocket in 2023
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Via Benzinga
Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
FibroGen Concludes Dosing In Late-Stage Blood Cell Disorder Study, Sees Top-line Data In H1 2023
Via Benzinga
FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Provides Update of its Investigation of the Officers and Directors of FibroGen, Inc. - FGEN
From Kahn Swick & Foti, LLC
Via Business Wire
Preview: FibroGen's Earnings
Via Benzinga
FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Provides Update of its Investigation of the Officers and Directors of FibroGen, Inc. - FGEN
From Kahn Swick & Foti, LLC
Via Business Wire
Akebia Therapeutics (AKBA) Stock Soars 18% Despite Lack of News
Via InvestorPlace
FibroGen, Inc. (NASDAQ:FGEN) Investor Alert: Investigation over Potential Wrongdoing
Via SBWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.